Latest News
Verastem, Inc.
- Verastem, Inc. Estimates – LS:A3EHM3
- Fierce Pharma Asia—Roche’s $1.2B obesity deal; Asahi Kasei’s FDA nod; Verastem’s KRAS boon
- Verastem prices $250m offering as KRAS drug heads to Phase III
- Verastem lays out argument for its KRAS inhibitor in PDAC and beyond
- Verastem makes its stand as a RevMed competitor in pancreatic cancer
- Verastem Gets a New CEO and $250 Million to Advance Its Cancer Pipeline
- Verastem raises USD 250m to advance VS-7375 KRAS G12D program
- Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
- Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
- Verastem cancer drug shows early promise in small study
- Verastem Oncology Names Michael Bailey CEO
- Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled
Headlines from the last 30 days, linking to the original publishers. See all market news →